Carman  Alenson net worth and biography

Carman Alenson Biography and Net Worth

Currently, Carman Alenson is Vice President-Accounting, Treasury & Tax at Agios Pharmaceuticals, Inc.

She received an MBA and an undergraduate degree from Boston University.

What is Carman Alenson's net worth?

The estimated net worth of Carman Alenson is at least $51,959.48 as of June 21st, 2021. Ms. Alenson owns 1,777 shares of Agios Pharmaceuticals stock worth more than $51,959 as of March 28th. This net worth estimate does not reflect any other investments that Ms. Alenson may own. Learn More about Carman Alenson's net worth.

How do I contact Carman Alenson?

The corporate mailing address for Ms. Alenson and other Agios Pharmaceuticals executives is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. Agios Pharmaceuticals can also be reached via phone at (617) 649-8600 and via email at [email protected]. Learn More on Carman Alenson's contact information.

Has Carman Alenson been buying or selling shares of Agios Pharmaceuticals?

Carman Alenson has not been actively trading shares of Agios Pharmaceuticals during the last quarter. Most recently, Carman Alenson sold 1,777 shares of the business's stock in a transaction on Monday, June 21st. The shares were sold at an average price of $61.61, for a transaction totalling $109,480.97. Following the completion of the sale, the insider now directly owns 1,777 shares of the company's stock, valued at $109,480.97. Learn More on Carman Alenson's trading history.

Who are Agios Pharmaceuticals' active insiders?

Agios Pharmaceuticals' insider roster includes Carman Alenson (Insider), Jonathan Biller (CFO & Head of Corp. Affairs ), Christopher Bowden (Insider), Jacqualyn Fouse (CEO & Director ), and Darrin Miles (Insider). Learn More on Agios Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Agios Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 23 times. They sold a total of 134,275 shares worth more than $3,371,241.80. The most recent insider tranaction occured on March, 5th when CEO Brian Goff sold 4,156 shares worth more than $135,360.92. Insiders at Agios Pharmaceuticals own 4.2% of the company. Learn More about insider trades at Agios Pharmaceuticals.

Information on this page was last updated on 3/5/2024.

Carman Alenson Insider Trading History at Agios Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/21/2021Sell1,777$61.61$109,480.971,777View SEC Filing Icon  
4/15/2021Sell991$54.00$53,514.00View SEC Filing Icon  
9/2/2020Sell250$39.93$9,982.50184View SEC Filing Icon  
12/26/2019Sell2,950$50.09$147,765.50View SEC Filing Icon  
7/9/2018Sell272$84.94$23,103.68272View SEC Filing Icon  
1/12/2018Sell2,150$75.00$161,250.002,150View SEC Filing Icon  
See Full Table

Carman Alenson Buying and Selling Activity at Agios Pharmaceuticals

This chart shows Carman Alenson's buying and selling at Agios Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Agios Pharmaceuticals Company Overview

Agios Pharmaceuticals logo
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $29.24
Low: $28.82
High: $29.42

50 Day Range

MA: $27.53
Low: $21.32
High: $34.81

2 Week Range

Now: $29.24
Low: $19.80
High: $35.50

Volume

434,786 shs

Average Volume

846,227 shs

Market Capitalization

$1.64 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84